Evidence map›Paper›PMID 41686383›Full record

ArticleDiscover oncology2026

HOXB2 is a prognostic biomarker and correlated with immune infiltration in colorectal cancer and glioma.

Zhenrui Liu, Puqiao Wen, Yuxuan Liao, Dawei Zhou, Hongyi Wang, Ruofan Xu, Zhen Zhang

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhenrui Liu *Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Puqiao Wen *Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yuxuan LiaoGraduate School of Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Dawei ZhouDepartment of Oncology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China.
Hongyi WangGraduate School of Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ruofan XuGraduate School of Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhen ZhangDepartment of Oncology, The Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, China. 819543490@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHOXB2 is a homeobox transcription factor whose dysregulation has been reported in multiple malignancies; however, its clinical relevance and associations with the tumor microenvironment (TME) in colorectal cancer (CRC) and low-grade glioma (LGG) remain incompletely characterized.

methodsPublic datasets and online platforms (PrognoScan, GEPIA2, TIMER, and Kaplan–Meier Plotter) were integrated to evaluate HOXB2 expression, survival outcomes, and correlations with tumor-infiltrating immune cell estimates in CRC and LGG. Associations between HOXB2 and immune marker genes were further assessed. In vitro, HOXB2 expression and biological effects were examined in glioma cells and normal brain cells using RT-qPCR, CCK-8 proliferation assays, Transwell invasion assays, and Western blotting. HOXB2 knockdown was additionally evaluated in the CRC cell line HT-29 using CCK-8, Transwell invasion assays, and Western blotting.

resultsAcross three CRC cohorts (GSE17536, GSE17537, and GSE14333), higher HOXB2 expression was significantly associated with poorer overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS). In LGG, higher HOXB2 expression was associated with worse OS (HR = 1.8, P = 0.00084) and DFS (HR = 1.5, P = 0.014). TIMER analyses indicated that HOXB2 expression was positively correlated with estimated infiltration levels of B cells, CD4⁺ and CD8⁺ T cells, macrophages, neutrophils, and dendritic cells in colon adenocarcinoma (COAD), rectum adenocarcinoma (READ), and LGG, and was also correlated with marker genes related to tumor-associated macrophages, regulatory T cells, and exhausted T cells. In vitro, HOXB2 expression was higher in glioma cells than in normal brain cells; HOXB2 knockdown reduced glioma cell proliferation and invasion and was accompanied by a decreased p-P65/P65 ratio. In HT-29 cells, HOXB2 knockdown similarly suppressed proliferation and invasion, and Western blotting confirmed effective HOXB2 downregulation.

conclusionsElevated HOXB2 expression is associated with adverse prognosis and with immune infiltration-related signatures in COAD, READ, and LGG. Together with in vitro findings, these results support HOXB2 as a potential prognostic biomarker and suggest a link between HOXB2 expression, immune-related features, and NF-κB-associated signaling; further pathway-focused and in vivo studies are needed to clarify underlying mechanisms and causality.

Indexed as

BiomarkerBrain lower grade of gliomaColorectal cancerHOXB2Immune infiltrationPrognosis

Identifiers

PMID41686383
PMCPMC13004770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.